Pembrolizumab or Placebo Plus Etoposide and Platinum as First …
WEBJul 20, 2020 · Purpose: Pembrolizumab monotherapy has shown antitumor activity in patients with small-cell lung cancer (SCLC). The randomized, double-blind, phase III KEYNOTE-604 study compared pembrolizumab plus etoposide and platinum (EP) with placebo plus EP for patients with previously untreated extensive-stage (ES) SCLC.
Perioperative Pembrolizumab for Early-Stage Non–Small-Cell Lung Cancer
WEBJun 3, 2023 · Among patients with resectable early-stage non–small-cell lung cancer (NSCLC), a perioperative approach that includes both neoadjuvant and adjuvant immune checkpoint inhibition may provide...
FDA approves pembrolizumab for metastatic small cell lung cancer
WEBOn June 17, 2019, the Food and Drug Administration granted accelerated approval to pembrolizumab (KEYTRUDA, Merck) for patients with metastatic small cell lung cancer (SCLC) with disease...
First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell …
WEBSep 25, 2018 · Clinical activity of immunotherapies has been observed in patients with refractory or metastatic small-cell lung cancer 8-12; however, a phase 2 single-group study of maintenance...
Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer
WEBApr 16, 2018 · Inhibitors of programmed death 1 (PD-1) and its ligand PD-L1 are effective therapies for metastatic non–small-cell lung cancer (NSCLC) lacking sensitizing EGFR or ALK mutations....
Pembrolizumab in Patients With Extensive-Stage Small-Cell Lung Cancer ...
WEBAug 16, 2017 · The safety and efficacy of pembrolizumab, a humanized monoclonal antibody against programmed death 1 (PD-1), were assessed in patients with programmed death ligand 1 (PD-L1)–expressing extensive-stage small-cell lung cancer (SCLC) in the multicohort, phase Ib open-label KEYNOTE-028 study (ClinicalTrials.gov identifier: NCT02054806).
Evidence to Date: Evaluating Pembrolizumab in the Treatment …
WEBJul 6, 2021 · Small-cell lung cancer (SCLC) is an aggressive subtype of lung cancer characterized by a rapid initial response and early development of resistance to systemic therapy and radiation. The management of SCLC significantly changed for the first time in decades with the introduction of immune checkpoint inhibitors.
Five-Year Outcomes With Pembrolizumab Versus Chemotherapy …
WEBKEYNOTE-042 is a randomized phase III study that showed significantly longer overall survival (OS) with pembrolizumab monotherapy versus platinum-based chemotherapy in patients with previously untreated locally advanced or metastatic non–small-cell lung cancer (NSCLC) with programmed death ligand-1 (PD-L1) tumor proportion score (TPS) ≥ 50% ...
Five-Year Outcomes With Pembrolizumab Versus Chemotherapy …
WEBApr 19, 2021 · Five-Year Outcomes With Pembrolizumab Versus Chemotherapy for Metastatic Non–Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50%. PURPOSEWe report the first 5-year follow-up of any first-line phase III immunotherapy trial for non–small-cell lung cancer (NSCLC). KEYNOTE-024 (ClinicalTrials.gov i...
Pembrolizumab versus placebo as adjuvant therapy for …
WEBSep 12, 2022 · Pembrolizumab is a standard-of-care for advanced non-small-cell lung cancer (NSCLC). We assessed pembrolizumab as adjuvant therapy for completely resected stage IB–IIIA NSCLC.